botox

Teva nears deal for Allergan's generic drugs unit: source

Teva Pharmaceutical Industries Ltd (TEVA.TA) is in advanced talks to buy Allergan Plc's (AGN.N) generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV (MYL.O), according to a person familiar with the matter.

Read Full Article

In Gaza, demand grows for a plastic surgeon's services

In a smart building in an upscale neighborhood of Gaza City, Salah El-Zanin is seeing a growing number of clients. Trained in Greece, he is the only plastic surgeon in Gaza with European qualifications, and his business is booming.

Read Full Article

Salix Pharma to restate past seven quarters' results

Salix Pharmaceuticals Ltd said it would restate financial statements for all of 2013 and the first three quarters of 2014, adding to the drugmaker's list of woes.

Read Full Article

Ackman's Pershing Square sees big payoff from Allergan deal

Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

Read Full Article

Valeant Pharma says may buy back up to $2 billion worth of securities

Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities.

Read Full Article

Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source

Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.

Read Full Article

Allergan says has been approached by another party about a deal

Botox maker Allergan Inc (AGN.N), fighting a hostile takeover bid by Valeant Pharmaceuticals Inc (VRX.TO), said on Monday it was approached about a potential transaction by another party, identified as Actavis Plc (ACT.N) by a source familiar with the situation.

Read Full Article

Valeant ready to raise Allergan bid to at least $200/share

Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) on Monday said in a letter to Allergan Inc's (AGN.N) board of directors that it was prepared to raise its offer to at least $200 per share but stopped short of doing so.

Read Full Article

Top Allergan holder Paulson urges deal with Shire: sources

Allergan Inc (AGN.N) shareholder Paulson & Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc (SHP.L) as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc (VRX.TO), according to two people familiar with the matter.

Read Full Article

Actavis plans new merger approach for Allergan - sources

Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Read Full Article

ISS urges Allergan to give investors vote, questions credibility

Prominent investor shareholder advisory firm ISS called on Allergan Inc to give its shareholders a chance to vote on any large, buyout-blocking acquisitions and said the company's board faced a credibility problem, according to a report seen by Reuters.

Read Full Article

Ackman's Pershing Square raises $3 billion in fund listing

Pershing Square Holdings, a fund managed by activist investor Bill Ackman, raised $3.07 billion ahead of a stock market listing in Amsterdam, the company said on Wednesday.

Read Full Article

Shareholder T. Rowe Price urges Allergan to hold off on deals

T. Rowe Price, the second largest shareholder in Allergan Inc (AGN.N), said on Friday that it wants the company to hold off on making major moves before a Dec. 18 special shareholder meeting, and criticized the board on its corporate governance.

Read Full Article

ValueAct returns to Valeant board, plans to raise stake

Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company.

Read Full Article

Top investors push Salix to abandon Cosmo deal - sources

Some of the top 20 investors at Salix Pharmaceuticals Ltd (SLXP.O) are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA (COPN.S), and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

Read Full Article
1 2

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics